TrialInternational journal of radiation oncology, biology, physics2015

Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.

Ritsuko Komaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.